Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Companyâs core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. Source
No articles found.
SmileDirectClub was founded on one simple belief: everyone deserves a smile they l...
SmileDirectClub was founded on one simple belie...
Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and ...
Founded in 1996 as a spinoff from the Harvard-M...
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...
Immunomedics is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
Anavex utilizes precision genetic medicine to treat severe and devastating neurolo...
Anavex utilizes precision genetic medicine to t...
Join the National Investor Network and get the latest information with your interests in mind.